466 Use of a 27-gene immuno-oncology (IO) assay to associate response to single-agent immune checkpoint inhibitor (ICI) therapy in advanced-stage NSCLC patients from a large Canadian cohort

• Tyler Nielsen,
• Rob Seitz,
• Douglas Ross,
• David Hout,
• Brock Schweitzer,
• David Gandara,
• David Saltman,
• Nicole Croteau,
• Heather Lockyer,
• Frank McMahon,
• Jeremy Spille,
• Andrea Dickey,
• Matthew Varga,
• Kim McGregor

Affiliations

Tyler Nielsen

Oncocyte Corporation, Nashville, TN, USA

Rob Seitz

Oncocyte Corporation, Nashville, TN, USA

Douglas Ross

Oncocyte Corporation, Nashville, TN, USA

David Hout

Oncocyte Corporation, Nashville, TN, USA

Brock Schweitzer

Oncocyte Corporation, Nashville, TN, USA

David Gandara

Department of Internal Medicine, UC Davis Comprehensive Cancer Center, Sacramento, California, USA

David Saltman

1BC Cancer, Victoria, Canada

Nicole Croteau

2The University of British Columbia, Victoria, Canada

Heather Lockyer

1BC Cancer, Victoria, Canada

Frank McMahon

3Oncocyte Corporation, Nashville, TN, USA

Jeremy Spille

3Oncocyte Corporation, Nashville, TN, USA

Andrea Dickey

3Oncocyte Corporation, Nashville, TN, USA

Matthew Varga

3Oncocyte Corporation, Nashville, TN, USA

Kim McGregor

3Oncocyte Corporation, Nashville, TN, USA